Cytiva Unveils Faster Biacore SPR Platform

Cytiva, is introducing the next generation of its Biacore 8 series SPR systems, enabling scientists to generate reliable interaction data faster, as drug discovery grows more complex. The new Biacore 8S and Biacore 8S+ systems bring together rapid screening and high-quality molecular characterization in a single system, reducing hands-on time through integrated plate handling, automated workflows, and extended unattended operation, without compromising data quality. 

Tim Bervoets, President, Discovery & Medical, Cytiva, says: “Scientists are being asked to move faster while working with increasingly complex molecules and tighter resources. The next generation of Biacore 8 series systems is designed to help teams focus their time and investment on the most promising candidates by delivering confident interaction data earlier in the discovery process.” 

The systems can screen 384 proteins in approximately 15 minutes, 16 times faster than the previous generation. This allows scientists to scale screening activities, while further improving the ability to resolve the most challenging interactions in late-stage characterization. 

As part of this update, Cytiva is also advancing its Biacore Insight Software v7.0 with Sensorgram comparison, a feature that converts full interaction profiles into an objective similarity score. This gives scientists a clearer way to assess comparability against a reference sample and supports applications such as biosimilar comparability, batch-to-batch monitoring, and assessing the impact of process and formulation changes. It also supports outputs aligned with comparative analytical assessment and 21 CFR Part 11 compliance. 

The Biacore 8S and Biacore 8S+ systems and the Biacore Insight Software v7.0 will be available to order in the summer of 2026. 

Cytiva, the drop logo, Biacore 8S system, Biacore 8S+ system, Biacore 8 series SPR system, and Biacore Insight Software with Senorgam comparison are trademarks of Global Life Sciences Solutions USA LLC or an affiliate doing business as Cytiva. 

This article has been republished from external sources. Note: Material may have been edited for clarity, length, or style. For more information, please contact the cited source.